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Summary Peripheral blood lymphocytes from female patients with early breast cancer were examined before
surgery for their ability to develop a primary antibody response in vitro against sheep red blood cells in soft
agar cultures containing autologous plasma. After 6 days incubation, foci of proliferating hemolysin-forming
cells surrounded by a lytic area were detected on the surface of the plates and counted with a dissection
microscope; this response was antigen-dependent and antigen-specific. We applied this assay to a group of
women suffering from early breast cancer and devoid of distant metastases. From our data, it appears that if
all the patients are grouped together, cancer-bearing women produce somewhat fewer (P<0.05) haemolytic
foci than healthy controls. However, division of the cancer patients into two subgroups, according to the
TNM pretreatment clinical classification ofregional lymph nodes, generated an interesting finding: N1 patients
(Nlb or NIa) produced definitely fewer foci than No patients, and the difference was highly statistically
significant (P<0.OO1). The depression of anti sheep red blood cell antibody production observed in N
patients was unrelated to the presence or absence of metastatic growth in their regional lymph nodes.
A method for growing peripheral blood
lymphocytes (PBL) in semisolid media and
measuring specific antibody responses has been
developed. PBL (9 x 106) from normal donors, after
4-6 days of culture in soft-agar containing sheep
red blood cells (SRBC) and autologous plasma,
produce an average of 35-40 foci of anti-SRBC
antibody-forming cells, which are easily scored
because of surrounding areas of haemolysis (Villa &
Clerici, 1981). This technique, which is relatively
easy to perform and results of which are
.eproducible, has been devised to assay antibody
production and immunoregulation in pathological
conditions associated with immune disorders,
particularly with malignant neoplasms.
The present paper deals with an attempt to
further improve our culture method and to apply it
to the study of the immune response in patients
with breast carcinoma. Breast cancer has been
chosen because it is linked with several distinctive
alterations of immune responsiveness both in
peripheral blood lymphocytes and regional lymph
nodes, which take place from the early stages of
disease (Nathanson, 1977). Our purpose was to
correlate the primary anti-SRBC antibody response
with the stage of the disease and the involvement of
axillary lymph nodes.
Materials and methods
Patients
The patient material of 77 cases was composed of
females with suspected operable breast cancer, not
previously treated elsewhere, observed, at the
National Cancer Institute of Milan, from October
1980 to December 1981. Age distribution ranged
between the 2nd and 6th decade, except for 2
patients aged 70 and 73 years. All patients were
thoroughly examined by clinical and laboratory
procedures, including complete skeletal X-rays
survey, liver scan etc. Exact staging, based on the
above evidence and on the postoperative
histopathological report of the breast tumour and
axillary lymph nodes, was determined and reported
according to the rules of the "TNM classification
of malignant tumours" (WHO, 1968). All blood
samples were taken before biopsy and surgical
operation, and investigators performing
immunological assays were unaware of the
pretreatment clinical classification of the case under
examination.
Controls
A control group of 60 healthy women, taken from
blood donors, was evaluated in parallel for
comparison. Patients and controls were rather
evenly matched for age; 77% of controls and 71%
of patients ranged between the 3rd and 5th decade.
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Lymphocyte separation
Human PBL were isolated from heparinized blood
by Ficoll Hypaque density centrifugation (Boyum,
1968). The plasma on the top of the gradient and
the cells at the interface were harvested. The cells
were washed twice in Dulbecco's modified Eagle
Medium (DMEM) and suspended at a
concentration of 3 x 106ml- in autologous plasma.
Lymphocyte cultures
The method of culturing PBL, previously described
(Villa & Clerici, 1981), was used with some
modifications. Briefly, double strength (2 x) DMEM
(Gibco) was supplemented with penicillin
(100Uml-1), 3mM reduced glutathione (GSH),
0.1% transferrin, and 15x10-5M 2-
mercaptoethanol (2-ME). Cultures were set up in
60mm plastic Petri dishes, and base layers were
made by mixing equal volumes of 1% agar (Noble,
Difco Lab. Inc., Detroit) and 2 x supplemented
DMEM, to which autologous plasma (final
concentration 10%) was added. Six ml aliquots of
this mixture were poured into Petri dishes and
allowed to gel at room temperature for 15min. The
overlay medium was prepared in such a way that
each ml contained 0.33% agar in supplemented
DMEM, 3 x 106 PBL in 15% autologous plasma,
10% washed SRBC, 8% polyethylene glycol (PEG)
6000 (Serva), and 0.3 ug% DEAE dextran (final
concentrations in cultures are indicated). Three ml
aliquots of this mixture, which was kept warm at
40°C, were then pipetted into the previously
prepared base layers. After cooling at room
temperature, the plates were incubated for 6 days at
37°C in a humidified incubator with constant flow
of 10% CO2 in air.
In the present paper, we have modified our
previous culture technique (Villa & Clerici, 1981) to
protect the responding lymphocytes from oxidative
insults, arising from the environment (high pO2) or
from metabolism (production of superoxide anions
and hydrogen peroxide by macrophages). We added
transferrin, as suggested by Iscove and Melchers
(1978), and reduced GSH, whose high content in
foetal calf serum (FCS) accounts for its usefulness
in murine cell cultures (Hoffeld & Oppenheim,
1980) and whose promoting activity on human PBL
proliferation has been recently demonstrated
(Hoffeld, 1981; Noelle & Lawrence, 1981). GSH,
together with 2-ME, which prevents its spontaneous
oxidation, allowed us to eliminate FCS and avoid
the use of a special low oxygen-tension mixture in
the incubation chamber.
Haemolyticfoci and cell-colony counting
Haemolytic foci and cell-colony counting were done
with a dissection microscope at x 10 magnification
using an ocular micrometer. Counting was further
facilitated by staining the entire plate with
benzidine. For demonstration of cell colonies in the
center of the plaques, cultures were stained with a
diluted solution of acridine orange in PBS, pH7.2
and observed under a fluorescence microscope.
Results
Clinical staging and post-surgical histopathological
assessment
In 58/77 patients, the diagnosis of breast carcinoma
was confirmed histologically; 44 patients showed
infiltrating ductal carcinoma, 10 infiltrating lobular
carcinoma, 3 mixed ductal and lobular carcinoma,
and 1 Paget carcinoma. In the remaining 19
patients, the lesions were found to be benign
(fibrocystic diseases, epithelial duct hypertrophy
and lipophagic granulomas).
Table I summarizes the clinical pretreatment
classification of primary tumours (T), regional
lymph nodes (N), distant metastases (M), and the
post-surgical histopathological assessment of
resected lymph nodes from patients with malignant
disease. Most of the cases (88%) showed a primary
mass that measured <5cm (Tog T1 and T2); about
half of these patients had no palpable axillary
lymph nodes (NO), and the other half had palpable
axillary lymph nodes (N1), either suspected (Nib) or
not-suspected (Nia) to be neoplastic. The post-
surgical histological examination showed that 30%
of No patients and 57% of N1 patients (Nla+Nlb)
had one or more tumour-positive nodes (N+). The
remaining N1 patients had hyperplastic nodes free
of metastatic growth (N-). The enlarged lymph
nodes showed sinus histiocytosis and/or hyperplasia
of the paracortical areas.
Anti-SRBCfociproduction
Figure 1 shows the number of haemolytic anti-
SRBC foci produced by women with breast
carcinoma, benign breast lesions and normal
controls. Cancer-bearing women produced less
haemolytic foci than blood donors (median value,
20 vs 30), and the difference was statistically
significant by the Mann-Whitney U-test (P<0.05).
Although patients with benign breast lesions
produced a relevant number of foci (median value,
40), they were excluded from statistical evaluation
due to the limited extent of their group. No
correlation between age and foci production was
found in controls or in any of the patient groups.ANTIBODY PRODUCTION IN BREAST CANCER PATIENTS 413
Table I Clinical pretreatment classification of malignant breast cancers and postsurgical histopathological assessment of
axillary lymph nodes.
Postsurgical histopathology ofresected axillary lymph nodes
Pretreatment clini- Tumour-negative nodes (N-) Tumour-positive nodes (N+)
cal classification
No. ofnodes containing growth No. ofnodes containing growth
TNM stage No. of No. of No. of
groups cases cases No. ofnodes examined cases No. ofnodes examined
TONOMO 14 11 0:16, 0:14, 0:11, 0:24, 0:18, 0:13, 0:10, 3 3:18, 10:19, 1:14
0:10, 0:17, 0:6, 0:10
TlNlbMo 5 3 0:22, 0:15, 0:18 2 7:18, 1:10
T2NOMO 11 7 0:25, 0:23, 0:20, 0:15, 0:25, 0:15, 0:14 4 2:15, 7:17, 1:15, 1:10
T2NiaM0 7 2 0:17, 0:12 5 1:17, 4:23, 1:17, 1:19, 3:20
T2NlbMO 14 7 0:19, 0:24, 0:15, 0:16, 0:12, 0:20, 0:22 7 1:24, 13:20, 3:15, 10:20, 7:20
18:33, 1:20
T3NOMO 2 1 0:9 1 2:20
T3NlbMo 1 1 11:18
T4NOMO 1 1 0:9
TXNoMo 1 1 8:15
TXNlbMo 1 1 1:13
Paget No 1 1 0:21
Total 58 33 25
T: primary tumour extent; N: condition of regional lymph nodes; M: absence or presence of distant metastases (13).
N+: patients with one or more nodes containing growth; N-: patients with all nodes free of metastases. The number of
nodes containing growth, if any, and the total number of nodes examined are shown for each patient.
Relationship between lymph node assessment and
anti-SRBCfoci production
Figure 2 summarizes the number of haemolytic foci
produced by PBL of patients belonging to the No
and N1 groups (N1=Nia+Nlb), irrespective of the
extent of their primary tumours. The data show a
reduction in the antibody production by N1 as
compared to No patients (median value, 13.5 vs. 29)
and the difference was highly statistically significant
(P<0.001) by the Mann-Whitney U-test.
Figure 3 compares the frequency distribution of
foci in the control group and in No and Ni
patients: 46% of controls and 47% of No patients
vs 82% N1 patients fell within the 1-25 range. The
remaining N1 patients (28%) were in the 26-50
range. None of the N1 patients vs 36% of controls
and 30% ofNo, respectively, produced >50 foci.
In Figure 4, the data from No and N1 groups are
split according to the histopathology of axillary
nodes into 4 subgroups, i.e., N1N-, NIN+,
NoN-,NoN+. Statistical comparison between the
subgroups N1N- and N1N+ showed that neither
the presence nor the absence of metastases
interfered with anti-SRBC foci production. As
regards the NoN- and NoN+ subgroups, no
statistical evaluation could be applied due to the
unequal distribution of the data.
Discussion
The present paper deals with the primary anti-
SRBC antibody response in cultures of peripheral
blood lymphocytes from patients with breast
carcinoma. Human breast cancer offers a useful
model because several women with early and
advanced disease have been extensively studied in
the past years by conventional in vivo and in vitro
immunological assays (Nathanson, 1977). However,
in the in vitro studies the lymphoid cells have been
generally triggered by the use of polyclonal
activators, rather than by defined antigens. This
approach is fraught with the problem of
extrapolating the results to antigen-specific immune
mechanisms. We have overcome this obstacle and
succeeded in developing a reproducible culture
system for inducing antibody responses with human
peripheral blood cells, based on the use of PEG
6000. This system is antigen-dependent and antigen-
specific, as recently confirmed also by Luzzati et al.
(1981), who were able to obtain an anti-SRBC
response by adding PEG to their PBL cultures.
Briefly, PBL are cultured in soft agar together
with SRBC and autologous fresh plasma in
DMEM+8% PEG. After 6 days incubation, foci
of proliferating haemolysin-forming cells
surrounded by a lytic area are detected on the414 M.L. VILLA et al.
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Figure 1 Haemolytic foci production by PBL from
breast cancer patients,. patients with breast lesions, and
healthy controls.
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Figure 2 Haemolytic foci production by PBL from
No and N1 patients. No, patients without palpable
axillary nodes; N1, patients with palpable axillary
nodes.
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Figure 3 Frequency distribution (%) of anti-SRBC foci production by PBL from healthy controls (open
bars), breast cancer patients with No axillary nodes (cross-hatched bars), and with N. axillary nodes (solid
bars).
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Figure 4 Haemolytic foci production by PBL from
breast patients with no palpable, tumor-negative
(NON-) or positive (NON+) nodes, or with palpable,
tumor negative (N1N-) or positive (N1N+) nodes.
surface of the plates and counted with a dissection
microscope at 10 xmagnification. We decided to
culture PBL in the presence of autologous plasma
to 1) avoid any supplementary stimulation arising
from xeno- and/or allogeneic antigens such as FCS
or pooled human plasma and 2) induce the immune
responses in an environment mimicking the in vivo
one, where lymphocyte functions are modulated by
plasma factors, either normal or tumour-induced.
We have applied this assay to PBL from a group
of women with suspected early breast cancer,
following clinical examination and before surgery.
After surgery and histopathological assessment, in
58 patients the diagnosis of malignant breast cancer
was confirmed, whereas 19 showed benign breast
lesions; all cancer patients were free of distant
metastases. From our data it appears that cancer-
bearing women produce somewhat fewer
haemolytic foci than normal subjects, if all patients
are grouped together. However, division into 2
subgroups, according to the TNM pretreatment
clinical classification of the regional lymph nodes,
showed that N1 patients, either Nia or Nib,
produced definitely fewer foci than N0 patients
(median value: 13.5 vs 29.0), the difference being
highly statistically significant by the Mann-Whitney
U-test (P<0.001) (Figure 2).
The frequency distribution of haemolytic foci
shows that 82% of N1 patients vs 46% of controls
produced a number of foci ranging from 1-25 and
that none of the N1 patients vs 30% of No and
36% ofcontrols produced >50 foci (Figure 3).
The depression of anti-SRBC antibody
production observed in N1 patients is, quite
remarkably, unrelated to the presence or absence of
metastatic growth in their regional lymph nodes.
Indeed, if these patients are regrouped as N1N+
and N1N-, according to post-surgical
histopathological findings, and compared by the
Mann-Whitney U-test, no significant differences
are observed (Figure 4).
From these results it appears that the anti-SRBC
immune responses of patients with a localized
cancer correlate better with the enlargement rather
than with the metastatic invasion of regional lymph
nodes. Other authors have reported similar
findings. Adler et al. (1980) found that small
tumours with nodal involvement inhibited immune
responsiveness more than those with no palpable
homolateral axillary lymph nodes (NO).
The relationship between axillary node
enlargement and impaired immune responsiveness
in peripheral blood is, for the time being, only a
matter of hypothesis. We tentatively suggest that
either soluble or cellular factors, released from the
breast tumour and/or from the activated axillary
node cells, may be responsible for restraining the
anti-SRBC response in N1 patients. Axillary nodes
provide the first setting where antigen(s) released by
the tumour stimulate the immunocompetent cells.
Data from previous investigations suggest that
locally-generated effector cells and their secretory
products bring about a specific depression of the
lymphocyte reactivity against non-tumour-related
agents (recall antigens skin testing, PHA
stimulation, mixed leukocyte reactions) (Whitthaker
& Clark, 1971; Ellis et al., 1975; Whitehead et al.,
1976; Nathanson, 1977; Adler et al., 1980;
Cannon et al., 1981).
An alternative hypothesis is that lymph node
enlargement and impaired antibody production are
manifestations of a defect in immune mechanisms
that precedes the neoplastic growth. In other
words, deterioration of the immune reactivity of
breast cancer patients may be patient- rather than
disease-related. We are trying to identify the
factor(s), if any, that induce immunodepression in
early breast cancer and to verify, by long-term
0416 M.L. VILLA et al.
follow-up of mastectomy patients, if poor antibody
production may have some prognostic relevance.
This work was supported by grant.82/00274.96 from the
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